U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H31N3O5.C4H4O4
Molecular Weight 533.5708
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CINEPAZIDE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.COC1=CC(=CC(OC)=C1OC)\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2

InChI

InChIKey=XSTJTOKYCAJVMJ-GVTSEVKNSA-N
InChI=1S/C22H31N3O5.C4H4O4/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24;5-3(6)1-2-4(7)8/h6-7,14-15H,4-5,8-13,16H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b7-6+;2-1-

HIDE SMILES / InChI

Molecular Formula C22H31N3O5
Molecular Weight 417.4986
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Cinepazide or cinepazide maleate (Kelinao or Anjieli in China) is a vasodilator used in China for the treatment of cardiovascular and cerebrovascular diseases, and peripheral vascular diseases. As a calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cells and relax smooth muscles of cerebral vessels, coronary arteries and peripheral vessels so as to relieve vasospasm, reduce vascular resistance, improve flexibility of red blood cells, increase blood circulation in cerebral vessels and improve microcirculation and brain metabolism. Cinepazide could also increase the number of cAMP by inhibiting cAMP phosphodiesterase and reduce oxygen consumption. In April 2002, cinepazide of Beijing Hwellso Pharmaceutical Co., Ltd was approved to enter the market with two dosage forms of oral formulation and injection under the trade name of Kelinao. Currently, Kelinao is the only domestic brand for the treatment of cardiovascular diseases. And in 2009, cinepazide was included in the national medicare drug list. Cinepazide maleate, after wide application, has gained the recognition of Chinese doctors and patients for the treatment of cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, cerebral hemorrhage sequel and post-traumatic brain syndrome. Besides, due to its efficacy in cardiovascular diseases and peripheral vascular diseases, cinepazide maleate has become a leading product in cerebrovascular drug market.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of cinepazide on the purinergic responses in the dog cerebral artery.
1984
Patents

Patents

Sample Use Guides

In Vivo Use Guide
2ml:80mg/Ampoule
Route of Administration: Intravenous
In Vitro Use Guide
cinepazide in concentrations ranging from 10(-6) to 10(-5) M selectively potentiates the relaxing response mediated through purinergic P1-receptors.
Substance Class Chemical
Created
by admin
on Tue Oct 22 13:55:06 UTC 2019
Edited
by admin
on Tue Oct 22 13:55:06 UTC 2019
Record UNII
Y35B3VA60V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CINEPAZIDE MALEATE
JAN   MART.   MI   WHO-DD  
Common Name English
CINEPAZIDE MALEATE [MI]
Common Name English
CINEPAZIDE MALEATE [WHO-DD]
Common Name English
VASODISTAL
Brand Name English
2-PROPEN-1-ONE, 1-(4-(2-OXO-2-(1-PYRROLIDINYL)ETHYL)-1-PIPERAZINYL)-3-(3,4,5-TRIMETHOXYPHENYL)-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
1-(2-OXO-2-(1-PYRROLIDINYL)ETHYL)-4-(1-OXO-3-(3,4,5-TRIMETHOXYPHENYL)-2-PROPENYL)PIPERAZINE (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
1-((1-PYRROLIDINYLCARBONYL)METHYL)-4-(3,4,5-TRIMETHOXYCINNAMOYL)PIPERAZINE MALEATE
Systematic Name English
NSC-291562
Code English
MD 67350
Code English
MD-67350
Code English
CINEPAZIDE MALEATE [MART.]
Common Name English
CINEPAZIDE MALEATE [JAN]
Common Name English
BRENDIL
Brand Name English
Code System Code Type Description
CAS
26328-04-1
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
MERCK INDEX
M1071
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY Merck Index
ChEMBL
CHEMBL1874750
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
PUBCHEM
5282458
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
EVMPD
SUB01311MIG
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
ECHA (EC/EINECS)
247-613-1
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
EPA CompTox
26328-04-1
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
PRIMARY
CAS
1202583-45-6
Created by admin on Tue Oct 22 13:55:07 UTC 2019 , Edited by admin on Tue Oct 22 13:55:07 UTC 2019
ALTERNATIVE
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY